CollPlant Biotechnologies Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on March 8, 2018, reports on the completion of specific closings under private placement securities purchase agreements entered into in November 2017. The filing details the issuance of warrants to investors Meitav Dash Provident Funds and Pension Ltd. and Ami Sagi.
Key Financial Metrics and Transaction Details
The filing does not provide consolidated revenue, profit, cash flow, or margin data for the reporting period. It focuses exclusively on capital raising activities:
- Meitav Dash Transaction: Completed the third closing on March 7, 2018, issuing warrants to purchase 11,900,000 ordinary shares (238,000 ADSs). Previous closings in December 2017 raised approximately $1,384,824.
- Ami Sagi Transaction: Completed the second closing on March 7, 2018, issuing warrants to purchase 9,300,000 ordinary shares (186,000 ADSs). The first closing in December 2017 raised approximately $1,054,122.
- Warrant Terms: Exercise price is the USD equivalent of NIS 40 per ADS. Warrants are exercisable for five years from issuance.
Material Changes and Unusual Items
The primary material change is the issuance of the warrants described above, which were issued for no additional consideration at the time of the March 7, 2018 closing. The warrants include significant anti-dilution protections:
- Standard adjustments for share splits, dividends, and fundamental transactions.
- Full-Ratchet Protection: A side letter grants full-ratchet anti-dilution protection until the second anniversary of the first closing if the company issues equity at a price lower than the original purchase price.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or specific risk factors beyond the terms of the securities issued. The securities were offered in an offshore transaction relying on Regulation S exemptions.
Investor Verification Checklist
- Verify the current share count and the potential dilution impact of the 21,200,000 ordinary shares underlying the newly issued warrants.
- Review the "full-ratchet" anti-dilution clause to understand the potential cost to existing shareholders if future equity is issued below the NIS 40 per ADS threshold.
- Confirm the total cash proceeds received from the December 2017 closings (approximately $2.44 million combined) and their current utilization.
- Check subsequent filings for any new equity issuances that might trigger the anti-dilution adjustments.